ES2461799T3 - Derivados de indolil-piridona que tienen actividad inhibidora de la quinasa de control 1 - Google Patents

Derivados de indolil-piridona que tienen actividad inhibidora de la quinasa de control 1 Download PDF

Info

Publication number
ES2461799T3
ES2461799T3 ES09704645T ES09704645T ES2461799T3 ES 2461799 T3 ES2461799 T3 ES 2461799T3 ES 09704645 T ES09704645 T ES 09704645T ES 09704645 T ES09704645 T ES 09704645T ES 2461799 T3 ES2461799 T3 ES 2461799T3
Authority
ES
Spain
Prior art keywords
title compound
oxo
dihydro
alkyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09704645T
Other languages
English (en)
Spanish (es)
Inventor
Stephen Stokes
Nicolas Foloppe
Andrea Fiumana
Martin Drysdale
Simon Bedford
Paul Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0801090.2A external-priority patent/GB0801090D0/en
Priority claimed from GBGB0818695.9A external-priority patent/GB0818695D0/en
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Application granted granted Critical
Publication of ES2461799T3 publication Critical patent/ES2461799T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES09704645T 2008-01-22 2009-01-20 Derivados de indolil-piridona que tienen actividad inhibidora de la quinasa de control 1 Active ES2461799T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0801090.2A GB0801090D0 (en) 2008-01-22 2008-01-22 New chemical compounds
GB0801090 2008-01-22
GB0818695 2008-10-11
GBGB0818695.9A GB0818695D0 (en) 2008-10-11 2008-10-11 New chemical compounds
PCT/GB2009/000149 WO2009093012A1 (en) 2008-01-22 2009-01-20 Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity

Publications (1)

Publication Number Publication Date
ES2461799T3 true ES2461799T3 (es) 2014-05-21

Family

ID=40377594

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09704645T Active ES2461799T3 (es) 2008-01-22 2009-01-20 Derivados de indolil-piridona que tienen actividad inhibidora de la quinasa de control 1

Country Status (17)

Country Link
US (5) US8916591B2 (OSRAM)
EP (1) EP2294065B1 (OSRAM)
JP (1) JP5386508B2 (OSRAM)
CN (1) CN101970424B (OSRAM)
AU (1) AU2009207478B2 (OSRAM)
BR (1) BRPI0906495B8 (OSRAM)
CA (1) CA2712959C (OSRAM)
DK (1) DK2294065T3 (OSRAM)
EA (1) EA021464B1 (OSRAM)
ES (1) ES2461799T3 (OSRAM)
IL (1) IL206808A (OSRAM)
MX (1) MX2010007525A (OSRAM)
NZ (1) NZ586756A (OSRAM)
PL (1) PL2294065T3 (OSRAM)
PT (1) PT2294065E (OSRAM)
WO (1) WO2009093012A1 (OSRAM)
ZA (1) ZA201005210B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916591B2 (en) 2008-01-22 2014-12-23 Vernalis (R&D) Ltd Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
GB0912499D0 (en) * 2009-07-18 2009-08-26 Vernalis R&D Ltd Indopyl-pyridone derivatives
KR101464060B1 (ko) 2010-04-07 2014-11-20 에프. 호프만-라 로슈 아게 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
WO2013045461A1 (en) 2011-09-27 2013-04-04 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
EP3024456A4 (en) 2013-07-26 2017-04-12 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
JP6704398B2 (ja) * 2015-01-28 2020-06-03 バイエル ファーマ アクチエンゲゼルシャフト 4H−ピロロ[3,2−c]ピリジン−4−オン誘導体
SG11202005700SA (en) * 2017-12-19 2020-07-29 Bristol Myers Squibb Co Amide substituted indole compounds useful as tlr inhibitors
KR20210038911A (ko) * 2018-07-24 2021-04-08 에피자임, 인코포레이티드 Smarca2 길항제로서 유용한 피리딘-2-온 화합물
US10280721B1 (en) 2018-07-27 2019-05-07 Upwing Energy, LLC Artificial lift
US10787873B2 (en) 2018-07-27 2020-09-29 Upwing Energy, LLC Recirculation isolator for artificial lift and method of use
US10370947B1 (en) * 2018-07-27 2019-08-06 Upwing Energy, LLC Artificial lift
US10253606B1 (en) 2018-07-27 2019-04-09 Upwing Energy, LLC Artificial lift
CA3109891A1 (en) * 2018-08-24 2020-02-27 Nanjing Transthera Biosciences Co., Ltd. Quinoline derivative inhibitor: tam, ntrk, and csf1r kinases
US11686161B2 (en) 2018-12-28 2023-06-27 Upwing Energy, Inc. System and method of transferring power within a wellbore
WO2021057782A1 (zh) * 2019-09-24 2021-04-01 南京药捷安康生物科技有限公司 杂环衍生物及其用途
JP2025523514A (ja) * 2022-06-24 2025-07-23 エナラーレ セラピューティクス インコーポレイテッド 神経性換気不全の処置方法
CN115594634B (zh) * 2022-10-26 2024-10-01 浙江工业大学 一种连续化制备4-硝基吡唑的新工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032615A3 (en) * 2001-03-28 2004-03-17 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
BR0213562A (pt) 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
EP1633694A4 (en) 2003-06-05 2007-03-14 Merck & Co Inc SUBSTITUTED INDOLE AND METHOD FOR THE PRODUCTION OF SUBSTITUTED INDOLE
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
CA2600914A1 (en) * 2005-01-28 2007-07-26 Mark E. Fraley Inhibitors of checkpoint kinases
JP2008545776A (ja) * 2005-06-11 2008-12-18 ヴァーナリス アールアンドディー リミテッド 癌および自己免疫疾患の治療における使用のためのピラゾール−置換ベンズイミダゾール誘導体
JP2009543770A (ja) * 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド Cdk及びgskの阻害のためのピラゾール誘導体の組合せ剤
WO2008025526A1 (en) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Indole derivatives, their manufacture and use as pharmaceutical agents
US8916591B2 (en) 2008-01-22 2014-12-23 Vernalis (R&D) Ltd Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
BRPI1012203A2 (pt) * 2009-05-15 2016-04-05 Novartis Ag derivados de 5-piridin-3-il-1,3-di-hidro-indol-2-ona e seu uso como moduladores da aldosterona sintase e/ou da cyp11b1

Also Published As

Publication number Publication date
EA201001197A1 (ru) 2011-04-29
BRPI0906495B8 (pt) 2021-05-25
US8916591B2 (en) 2014-12-23
EP2294065B1 (en) 2014-03-19
DK2294065T3 (da) 2014-04-28
CN101970424B (zh) 2013-06-12
IL206808A (en) 2015-08-31
US20170298043A1 (en) 2017-10-19
PL2294065T3 (pl) 2014-11-28
US20200361905A1 (en) 2020-11-19
BRPI0906495A8 (pt) 2015-10-06
CN101970424A (zh) 2011-02-09
PT2294065E (pt) 2014-05-15
EP2294065A1 (en) 2011-03-16
WO2009093012A1 (en) 2009-07-30
EA021464B1 (ru) 2015-06-30
CA2712959C (en) 2015-06-23
BRPI0906495A2 (pt) 2015-07-14
CA2712959A1 (en) 2009-07-30
AU2009207478A1 (en) 2009-07-30
US20110021498A1 (en) 2011-01-27
US10696652B2 (en) 2020-06-30
IL206808A0 (en) 2010-12-30
US20180244652A1 (en) 2018-08-30
NZ586756A (en) 2012-04-27
ZA201005210B (en) 2011-03-30
BRPI0906495B1 (pt) 2020-11-10
US20150099736A1 (en) 2015-04-09
JP5386508B2 (ja) 2014-01-15
AU2009207478B2 (en) 2013-11-21
MX2010007525A (es) 2010-08-18
JP2011510055A (ja) 2011-03-31
US9604975B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
ES2461799T3 (es) Derivados de indolil-piridona que tienen actividad inhibidora de la quinasa de control 1
US12404285B2 (en) KRAS G12D proteolysis targeting chimeras
ES2863474T3 (es) Compuestos de indol sustituidos con dimetoxifenilo como inhibidores de TLR7, TLR8 o TLR9
CN106170288B (zh) 药物化合物
ES2541493T3 (es) Derivados de benzopirazina sustituida como inhibidores de FGFR quinasa para el tratamiento de enfermedades cancerígenas
ES2679625T3 (es) 2-(Morfolin-4-il)-1,7-naftiridinas
ES2829636T3 (es) Pirazolo[3,4-b]piridin-6-carboxamidas N-sulfoniladas y método de uso
CA2862940C (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
BR112020011979A2 (pt) compostos de indol substituídos por amida úteis como inibidores de tlr
ES2287508T3 (es) Compuestos de triazol para el tratamiento de dismenorrea.
JP2019508384A (ja) 5−置換2−(モルホリン−4−イル)−1,7−ナフチリジン
ES2893154T3 (es) Derivados de tiazolopirimidina fusionados como inhibidores de MNKs
BR112021009430A2 (pt) inibidores de erk e usos dos mesmos
JP6762300B2 (ja) アミノピラゾール誘導体
CN120390740A (zh) 作为PI3Kα抑制剂的杂环化合物
CN118574827A (zh) Brm靶向化合物和相关的使用方法
HK1240227A1 (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors